{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(2)"],"submitter":["Liang X"],"pubmed_abstract":["1q gain/amplification (1q+) is the most common cytogenetic abnormality (CA), with a frequency of 30-50% in patients with newly diagnosed multiple myeloma (NDMM). Although accumulating evidence supports 1q+ as a \"high-risk\" CA (HRCA), several issues remain to be addressed to understand its true prognostic property. We retrospectively analyzed a cohort of 934 patients with NDMM from three centers in China, who had baseline data available for 1q+ [including 1q21 gain (3 copies) and amplification (> 3 copies)] detected by fluorescence in situ hybridization in isolated CD138<sup>+</sup> cells, and who received first-line treatment with novel agents including proteasome inhibitors, immunomodulatory drugs, or both. Minimal residue disease (MRD) was assessed using next-generation flow cytometry. I"],"journal":["American journal of cancer research"],"pagination":["501-516"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11897644"],"repository":["biostudies-literature"],"pubmed_title":["Dissecting the high-risk property of 1q gain/amplification in patients with newly diagnosed multiple myeloma."],"pmcid":["PMC11897644"],"pubmed_authors":["Yi X","Liang X","Zhu Y","Ma X","Zhang N","Long M","Yan Y","Sun X","Wang J","Sun Y","Dai Y","Jin F","Huang W","Zhang Y","Kumar SK","Lan M","Zhou F","Xu W","Hu R"],"additional_accession":[]},"is_claimable":false,"name":"Dissecting the high-risk property of 1q gain/amplification in patients with newly diagnosed multiple myeloma.","description":"1q gain/amplification (1q+) is the most common cytogenetic abnormality (CA), with a frequency of 30-50% in patients with newly diagnosed multiple myeloma (NDMM). Although accumulating evidence supports 1q+ as a \"high-risk\" CA (HRCA), several issues remain to be addressed to understand its true prognostic property. We retrospectively analyzed a cohort of 934 patients with NDMM from three centers in China, who had baseline data available for 1q+ [including 1q21 gain (3 copies) and amplification (> 3 copies)] detected by fluorescence in situ hybridization in isolated CD138<sup>+</sup> cells, and who received first-line treatment with novel agents including proteasome inhibitors, immunomodulatory drugs, or both. Minimal residue disease (MRD) was assessed using next-generation flow cytometry. I","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-01T22:48:26.478Z","creation":"2025-04-04T01:29:26.142Z"},"accession":"S-EPMC11897644","cross_references":{"pubmed":["40084363"],"doi":["10.62347/fxvh4425","10.62347/FXVH4425"]}}